Thrombectomy Devices Market - Growth, Trends, and Forecast (2019 - 2024)
|出版商||Mordor Intelligence LLP||商品編碼||907031|
|出版日期||內容資訊||英文 114 Pages
|全球血栓消除設備市場:成長，趨勢，預測 Thrombectomy Devices Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日期: 2019年06月01日||內容資訊: 英文 114 Pages||
The global population is aging rapidly, owing primarily to the reduced birth rates, stressed lifestyle, and increasing life expectancy. From 1961-2011, the percentage of elderly population increased from 5.6% - 8.6%, globally. The geriatric population is at greater risk in developing multiple diseases conditions, which would need surgical interventions for the treatment.
The number of older people is estimated to increase by nearly 60% in the next 15 years and by 2030, the total number of people aged above 65 is likely to be more than a billion, i.e., the geriatric population may represent 12% of the global population and by 2050, this number may cross 1.6 billion or 16.7% of the total population. According to the United Nation Economic and Social Commission for Asia and the Pacific (ESCAP) report, the geriatric population in Asia-Pacific was around 617.1 million in 2015, accounting for more than half of the world's total elderly population. It is estimated that, by 2050, the Asia-Pacific region may account for almost two-thirds of the world's geriatric population.
The growing trend of the geriatric population is leading to an increase in the prevalence of cardiovascular diseases. According to WHO, an estimated 17.7 million people died from CVDs in 2015, representing 31% of all global deaths. Of these deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke. The growing burden of strokes across the world is demanding innovative products with high efficacy, leading to growth in the sales of stent retrievers for effective thrombectomy related procedures, thus driving the thrombectomy devices market.
Thrombectomy is an interventional procedure performed to remove clots from a blood vessel. It is commonly performed in coronary arteries, peripheral arteries, and cerebral arteries.
Mechanical thrombectomy devices comprise a wide number of endovascular tools cleared for removing thrombi from the neurovasculature in acute ischemic stroke patients. There is a significant percentage of the stroke patient population who are eligible for treatment with thrombolysis. As per the NHS England commissionary policy reported in 2018, about 12% of all people with stroke are eligible for mechanical thrombectomy procedures.
Two of the first generation mechanical thrombectomy devices include the Merci Retriever system by Stryker and the Penumbra Aspiration device by Penumbra. These devices have been widely appreciated. Merci Retriever was among the first endovascular devices to receive FDA approval in the United States. There are several established players in this segment, such as Acandis, J&J, Sela Medical, among others.
The mechanical thrombectomy is one of the most used approaches to recanalization in patients with large-artery occlusion who have not responded to intravenous fibrinolysis. The demand is expected to be consistently growing and should be a major part of thrombectomy devices market because of its good success rate in reducing the stroke-related disability and mortality.
The increasing burden of cardiac patients, technological advancements in the devices to attain better clinical outcomes, and increasing demand for minimally invasive products are driving the thrombectomy devices market in the United States.
According to the CDC, nearly 800,000 (approximately 795,000) people in the United States have a stroke every year, with about three in four being first-time strokes. Stroke is the fifth major cause of death in the United States, killing nearly 130,000 people a year. The increasing burden of stroke is leading to an increasing demand for interventional procedures, which is driving the market.
As per a recent publication (2018) by American Heart Association (AHA) Journals, about only 2/3 of the US population have direct access to endovascular therapy (EVT) for stroke within an hour. This has raised concerns to improve the accessibility and shorten the time to EVT to give patients the best chance for an excellent outcome after strokes. The growth in the adoption rate has been steady with the focus on several other diseases, such as pulmonary embolism. Over the forecast period, the favorable reimbursement scenario for medical devices with the aforementioned factors, the market is estimated to grow consistently in the North America region.
The Thrombectomy market is moderately competitive and consists of global as well as local players. However, there are new entrants that are coming up in the market are expected to hold a substantial share. Stryker, Boston Scientific, Medtronic, Terumo Corporation are some of the global companies that are playing well in this market.